Meeting
2014 ASCO Annual Meeting
A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011).
Authors
Sarah K. Tasian
The Children's Hospital of Philadelphia, Philadelphia, PA
Sarah K. Tasian , Mignon L. Loh , Karen R. Rabin , Patrick Andrew Brown , Charlotte H. Ahern , Brenda Weigel , Susan Blaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT01164163
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10019)
DOI
10.1200/jco.2014.32.15_suppl.10019
Abstract #
10019
Poster Bd #
320
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC).
First Author: John Sarantopoulos
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Annual Meeting
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).
First Author: Álvaro Lassaletta
Poster
2023 ASCO Annual Meeting
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
First Author: David Sommerhalder